September 7, 2012
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that the Toronto Stock
Exchange has approved Helix’s proposal to extend the expiry date of the 2009 Warrants (as defined below)
by six months, from September 7, 2012 at 5:00 p.m. (Toronto time) (the “Current Expiry Date”) to March
7, 2013 at 5:00 p.m. (Toronto time). No other provision of the 2009 Warrants has been amended, and none
of the 2009 Warrants is held directly or indirectly by an insider of Helix.